AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of “Moderate Buy” by Brokerages

AnaptysBio, Inc. (NASDAQ:ANAB) has earned an average rating of “Moderate Buy” from the ten research firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $46.22.

A number of research firms recently weighed in on ANAB. Wells Fargo & Company began coverage on AnaptysBio in a report on Thursday, April 11th. They issued an “overweight” rating and a $56.00 price target on the stock. Wedbush raised AnaptysBio from a “neutral” rating to an “outperform” rating and upped their target price for the company from $20.00 to $34.00 in a research note on Tuesday, March 12th. JPMorgan Chase & Co. reduced their target price on AnaptysBio from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, April 1st. Leerink Partnrs reaffirmed an “outperform” rating on shares of AnaptysBio in a research note on Tuesday, April 16th. Finally, BTIG Research began coverage on AnaptysBio in a research note on Monday, February 26th. They issued a “buy” rating and a $55.00 target price on the stock.

Insiders Place Their Bets

In other AnaptysBio news, insider Eric J. Loumeau sold 5,000 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the insider now owns 3,240 shares of the company’s stock, valued at approximately $81,000. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Daniel Faga sold 145,940 shares of the stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $22.78, for a total value of $3,324,513.20. Following the transaction, the chief executive officer now directly owns 752,087 shares of the company’s stock, valued at approximately $17,132,541.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Eric J. Loumeau sold 5,000 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the transaction, the insider now directly owns 3,240 shares in the company, valued at $81,000. The disclosure for this sale can be found here. Insiders have sold a total of 153,940 shares of company stock valued at $3,513,773 in the last quarter. 35.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC purchased a new position in shares of AnaptysBio in the 1st quarter worth $38,000. China Universal Asset Management Co. Ltd. increased its holdings in AnaptysBio by 350.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 2,390 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in AnaptysBio by 134.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock valued at $106,000 after purchasing an additional 3,381 shares in the last quarter. Quest Partners LLC acquired a new stake in AnaptysBio in the 4th quarter valued at $119,000. Finally, SG Americas Securities LLC acquired a new stake in AnaptysBio in the 4th quarter valued at $126,000.

AnaptysBio Price Performance

ANAB opened at $24.34 on Wednesday. The stock has a market cap of $664.97 million, a P/E ratio of -4.00 and a beta of -0.30. The stock’s 50 day simple moving average is $22.88 and its 200 day simple moving average is $20.65. AnaptysBio has a 1-year low of $13.36 and a 1-year high of $27.50.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.15. The business had revenue of $9.01 million for the quarter, compared to analysts’ expectations of $3.28 million. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. Research analysts expect that AnaptysBio will post -6.17 EPS for the current fiscal year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.